Pondicherry Institute of Medical Sciences (PIMS Puducherry India.
Medanta - The Medicity Gurgaon India.
Endocrinol Diabetes Metab. 2021 Feb 8;4(3):e00231. doi: 10.1002/edm2.231. eCollection 2021 Jul.
Longitudinal data on progression, complications, and management of type 2 diabetes mellitus (T2DM) across India are scarce. LANDMARC (CTRI/2017/05/008452), the first -India, longitudinal, prospective, observational study, aims to understand the management and real-world outcomes of T2DM over 3 years.
Adults (≥25 to ≤60 years old at T2DM diagnosis; diabetes duration ≥2 years at enrollment; controlled/uncontrolled on ≥2 anti-diabetic agents) were enrolled. Baseline characteristics were analyzed using descriptive statistics.
Of the 6279 recruited participants, 6236 were eligible for baseline assessment (56.6% [/ = 3528/6236] men; mean ± SD age: 52.1 ± 9.2 years, diabetes duration: 8.6 ± 5.6 years). mean ± SD HbA1c, fasting plasma glucose, and postprandial glucose values were 64 ± 17 mmol/mol (8.1 ± 1.6%), 142.8 ± 50.4 mg/dl, and 205.7 ± 72.3 mg/dl, respectively. Only 25.1% (/ = 1122/6236) participants had controlled glycemia (HbA1c < 53 mmol/mol, <7%). Macrovascular and microvascular complications were prevalent in 2.3% (/ = 145/6236) and 14.5% (/ = 902/6236) participants, respectively. Among those with complications, non-fatal myocardial infarction (/ = 74/145, 51.0%) and neuropathy (/ = 737/902, 81.7%) were the most reported macrovascular and microvascular complication, respectively. Hypertension (/ = 2566/3281, 78.2%) and dyslipidemia (/ = 1635/3281, 49.8%) were the most reported cardiovascular risks. Majority (74.5%; / = 4643/6236) were taking oral anti-diabetic drugs (OADs) only, while 24.4% (/ = 1522/6236) participants were taking OADs+insulin. Biguanides (/ = 5796/6236, 92.9%) and sulfonylureas (/ = 4757/6236, 76.3%) were the most reported OADs. Basal (/ = 837/6236, 13.4%) and premix (/ = 684/6236, 11.0%) insulins were the most reported insulins.
Baseline data from LANDMARC help understand the clinical/medical profile of study participants and underscore the extent of suboptimal glycemic control and prevalence of associated complications in a vast majority of Indians with T2DM.
印度缺乏关于 2 型糖尿病(T2DM)进展、并发症和管理的纵向数据。LANDMARC(CTRI/2017/05/008452)是印度首个纵向、前瞻性、观察性研究,旨在了解 3 年内 T2DM 的管理和真实世界结局。
纳入成年人(T2DM 诊断时年龄≥25 岁且≤60 岁;糖尿病病程≥2 年;至少使用 2 种抗糖尿病药物血糖控制不佳/控制良好)。使用描述性统计方法分析基线特征。
在 6279 名招募的参与者中,有 6236 名符合基线评估条件(56.6%[3528/6236]为男性;平均±标准差年龄为 52.1±9.2 岁,糖尿病病程为 8.6±5.6 年)。平均±标准差糖化血红蛋白(HbA1c)、空腹血糖和餐后血糖值分别为 64±17mmol/mol(8.1±1.6%)、142.8±50.4mg/dl 和 205.7±72.3mg/dl。仅有 25.1%(1122/6236)的参与者血糖控制良好(HbA1c<53mmol/mol,<7%)。大血管和微血管并发症在 2.3%(145/6236)和 14.5%(902/6236)的参与者中较为常见。在有并发症的患者中,非致命性心肌梗死(74/145,51.0%)和神经病变(737/902,81.7%)是最常见的大血管和微血管并发症。高血压(2566/3281,78.2%)和血脂异常(1635/3281,49.8%)是最常见的心血管风险因素。大多数患者(74.5%,4643/6236)仅服用口服降糖药(OADs),而 24.4%(1522/6236)的患者同时服用 OADs+胰岛素。二甲双胍(5796/6236,92.9%)和磺脲类药物(4757/6236,76.3%)是最常使用的 OADs。基础胰岛素(837/6236,13.4%)和预混胰岛素(684/6236,11.0%)是最常使用的胰岛素。
LANDMARC 的基线数据有助于了解研究参与者的临床/医学特征,并强调了大多数印度 2 型糖尿病患者血糖控制不佳和相关并发症发生率较高的情况。